Comparing Decoy Therapeutics (DCOY) & Its Rivals

Decoy Therapeutics (NASDAQ:DCOY) is one of 458 public companies in the “Pharmaceutical Preparations” industry, but how does it weigh in compared to its rivals? We will compare Decoy Therapeutics to similar businesses based on the strength of its earnings, dividends, analyst recommendations, institutional ownership, risk, profitability and valuation.

Valuation & Earnings

This table compares Decoy Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Decoy Therapeutics	N/A	-$5.58 million	-0.02
Decoy Therapeutics Competitors	$432.12 million	-$67.78 million	-10.61

Decoy Therapeutics’ rivals have higher revenue, but lower earnings than Decoy Therapeutics. Decoy Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Decoy Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-401.05%	-155.77%
Decoy Therapeutics Competitors	-2,662.14%	-363.93%	-42.95%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Decoy Therapeutics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1	0	1	0	2.00
Decoy Therapeutics Competitors	4898	9969	15994	377	2.38

Decoy Therapeutics presently has a consensus target price of $2.50, indicating a potential upside of 267.11%. As a group, “Pharmaceutical Preparations” companies have a potential upside of 64.94%. Given Decoy Therapeutics’ higher possible upside, equities research analysts plainly believe Decoy Therapeutics is more favorable than its rivals.

Insider & Institutional Ownership

11.9% of Decoy Therapeutics shares are held by institutional investors. Comparatively, 39.1% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 0.3% of Decoy Therapeutics shares are held by insiders. Comparatively, 13.9% of shares of all “Pharmaceutical Preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Decoy Therapeutics has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Comparatively, Decoy Therapeutics’ rivals have a beta of 5.62, meaning that their average share price is 462% more volatile than the S&P 500.

Summary

Decoy Therapeutics rivals beat Decoy Therapeutics on 9 of the 13 factors compared.

Decoy Therapeutics Company Profile

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.